Latest News
Eli Lilly and Company reports positive one-year results for Omvoh in paediatric ulcerative colitis
19 October 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) reported on Mondy that it has recorded positive one-year Phase 3 results for Omvoh (mirikizumab-mrkz) in children and adolescents with moderately to severely active ulcerative colit...
Telix and Ekalia to develop US astatine-211 production
...
AbbVie's dual-targeting Crohn's disease therapy outperforms monotherapies in Phase IIa trial
19 October 2026 - Pharmaceutical research and development company AbbVie (NYSE: ABBV) reported on Monday that its investigational dual-targeting therapy ABBV-466 achieved higher endoscopic remission rates than either anti-IL-23 or anti-α4β...
Takeda trial shows ENTYVIO reduces ulcerative colitis complication risk by nearly 70%
19 October 2026 - Japan-based biopharmaceutical company Takeda (TSE: 4502) (NYSE: TAK) announced on Monday that positive Phase IV VERDICT trial results show that treating adults with moderate to severe ulcerative colitis with ENTYVIO (vedolizumab) to...
GSK reports 61% response rate for investigational lung cancer drug
19 October 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) on Monday reported a confirmed overall response rate of 61% for its investigational antibody-drug conjugate risvutatug rezetecan (Ris-Rez) at the 8 mg/kg dose in a Phase Ib tr...